We become the most trusted partner of our customers and make a better life for patients
Pipeline
KP-IB
Program Target
Integrin
Disease Indication
dry AMD
Normal retina
Intermediate dry AMD
late dry AMD
normal vision
dry AMD patient vision
Dry age-related macular degeneration non-neovascular form age-related macular degeneration about 90 percent of AMD patients leading cause of vision loss symptoms: blurred/black spots in central vision vision loss negatively impacts patient’s quality of life significantly
KP-IB mechanism
KP-IB novel integrin inhibitor potential First–in-Class Product for dry AMD a promising new therapeutic target for dry-AMD
PHONE
031-8025-6901
FAX
031-888-6699
Copyright 2021 KPBioscience. All right reserved.
Privacy | service | Contact us
